-
公开(公告)号：US07829665B2
公开(公告)日：2010-11-09
申请号：US11491126
申请日：2006-07-21
申请人： Lawrence M. Blatt , Scott D. Seiwert , Steven W. Andrews , Pierre Martin , Andreas Schumacher , Bradley Barnett , C. Todd Eary , Robert Kaus , Timothy Kercher , Weidong Liu , Michael Lyon , Paul Nichols , Bin Wang , Tarek Sammakia , April Kennedy , Yutong Jiang
发明人： Lawrence M. Blatt , Scott D. Seiwert , Steven W. Andrews , Pierre Martin , Andreas Schumacher , Bradley Barnett , C. Todd Eary , Robert Kaus , Timothy Kercher , Weidong Liu , Michael Lyon , Paul Nichols , Bin Wang , Tarek Sammakia , April Kennedy , Yutong Jiang
IPC分类号： C07K7/50
CPC分类号： C07K5/0806 , A61K38/00 , A61K38/1793 , A61K38/212 , A61K38/217 , A61K38/2292 , A61K38/55 , C07D471/04 , C07D487/04 , C07K5/0804 , A61K2300/00
摘要： The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
摘要翻译： 实施方案提供通式I至通式VIII的化合物，以及包含主题化合物的组合物，包括药物组合物。 实施方案还提供治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，所述方法通常涉及向有需要的个体施用有效量的主题化合物或组合物。
-
公开(公告)号：US20090148407A1
公开(公告)日：2009-06-11
申请号：US11996902
申请日：2006-07-17
申请人： Lawrence M. Blatt , Scott D. Seiwert , Steven W. Andrews , Pierre Martin , Andreas Schumacher , Bradley Barnett , C. Todd Eary , Robert Kaus , Timothy Kercher , Weidong Liu , Michael Lyon , Paul Nichols , Bin Wang , Tarek Sammakia , April Kennedy , Yutong Jiang
发明人： Lawrence M. Blatt , Scott D. Seiwert , Steven W. Andrews , Pierre Martin , Andreas Schumacher , Bradley Barnett , C. Todd Eary , Robert Kaus , Timothy Kercher , Weidong Liu , Michael Lyon , Paul Nichols , Bin Wang , Tarek Sammakia , April Kennedy , Yutong Jiang
IPC分类号： A61K38/21 , C07K5/12 , A61K38/12 , C07D209/18 , C12N9/99 , A61K39/395
CPC分类号： C07K5/0806 , A61K38/00 , A61K38/1793 , A61K38/212 , A61K38/217 , A61K38/2292 , A61K38/55 , C07D471/04 , C07D487/04 , C07K5/0804 , A61K2300/00
摘要： The embodiments provide compounds of the general Formulae (I) through general Formula (VIII), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
摘要翻译： 实施方案提供通式（I）至通式（VIII）的化合物，以及包含主题化合物的组合物，包括药物组合物。 实施方案还提供治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，所述方法通常涉及向有需要的个体施用有效量的主题化合物或组合物。
-
公开(公告)号：US08299021B2
公开(公告)日：2012-10-30
申请号：US13450885
申请日：2012-04-19
申请人： Lawrence M Blatt , Scott D Seiwert , Steven W Andrews , Pierre Martin , Andreas Schumacher , Bradley Barnett , C. Todd Eary , Robert Kaus , Timothy Kercher , Weidong Liu , Michael Lyon , Paul Nichols , Bin Wang , Tarek Sammakia , April Kennedy , Yutong Jiang
发明人： Lawrence M Blatt , Scott D Seiwert , Steven W Andrews , Pierre Martin , Andreas Schumacher , Bradley Barnett , C. Todd Eary , Robert Kaus , Timothy Kercher , Weidong Liu , Michael Lyon , Paul Nichols , Bin Wang , Tarek Sammakia , April Kennedy , Yutong Jiang
IPC分类号： A61K38/00
CPC分类号： C07K5/0806 , A61K38/00 , A61K38/1793 , A61K38/212 , A61K38/217 , A61K38/2292 , A61K38/55 , C07D471/04 , C07D487/04 , C07K5/0804 , A61K2300/00
摘要： The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
摘要翻译： 实施方案提供通式I至通式VIII的化合物，以及包含主题化合物的组合物，包括药物组合物。 实施方案还提供治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，所述方法通常涉及向有需要的个体施用有效量的主题化合物或组合物。
-
4.发明申请公开(公告)号：US20120208995A1
公开(公告)日：2012-08-16
申请号：US13450885
申请日：2012-04-19
申请人： Lawrence M. Blatt , Scott D. Seiwert , Steven W. Andrews , Pierre Martin , Andreas Schumacher , Bradley Barnett , C. Todd Eary , Robert Kaus , Timothy Kercher , Weidong Liu , Michael Lyon , Paul Nichols , Bin Wang , Tarek Sammakia , April Kennedy , Yutong Jiang
发明人： Lawrence M. Blatt , Scott D. Seiwert , Steven W. Andrews , Pierre Martin , Andreas Schumacher , Bradley Barnett , C. Todd Eary , Robert Kaus , Timothy Kercher , Weidong Liu , Michael Lyon , Paul Nichols , Bin Wang , Tarek Sammakia , April Kennedy , Yutong Jiang
IPC分类号： C07D498/18
CPC分类号： C07K5/0806 , A61K38/00 , A61K38/1793 , A61K38/212 , A61K38/217 , A61K38/2292 , A61K38/55 , C07D471/04 , C07D487/04 , C07K5/0804 , A61K2300/00
摘要： The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
摘要翻译： 实施方案提供通式I至通式VIII的化合物，以及包含主题化合物的组合物，包括药物组合物。 实施方案还提供治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，所述方法通常涉及向有需要的个体施用有效量的主题化合物或组合物。
-
5.发明申请NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION 审中-公开HEPATITIS C病毒复制的新型MACROCYCLIC抑制剂公开(公告)号：US20090169510A1
公开(公告)日：2009-07-02
申请号：US12106234
申请日：2008-04-18
申请人： Lawrence M Blatt , Scott D. Seiwert , Steven W. Andrews , Pierre Martin , Andreas Schumacher , Bradley Barnett , C. Todd Eary , Robert Kaus , Timothy Kercher , Weidong Liu , Michael Lyon , Paul Nichols , Bin Wang , Tarek Sammakia , April Kennedy , Yutong Jiang
发明人： Lawrence M Blatt , Scott D. Seiwert , Steven W. Andrews , Pierre Martin , Andreas Schumacher , Bradley Barnett , C. Todd Eary , Robert Kaus , Timothy Kercher , Weidong Liu , Michael Lyon , Paul Nichols , Bin Wang , Tarek Sammakia , April Kennedy , Yutong Jiang
CPC分类号： C07K5/0806 , A61K38/00 , A61K38/1793 , A61K38/212 , A61K38/217 , A61K38/2292 , A61K38/55 , C07D471/04 , C07D487/04 , C07K5/0804 , A61K2300/00
摘要： The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
摘要翻译： 实施方案提供通式I至通式VIII的化合物，以及包含主题化合物的组合物，包括药物组合物。 实施方案还提供治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，所述方法通常涉及向有需要的个体施用有效量的主题化合物或组合物。
-
公开(公告)号：US20070054842A1
公开(公告)日：2007-03-08
申请号：US11491126
申请日：2006-07-21
申请人： Lawrence Blatt , Scott Seiwert , Steven Andrews , Pierre Martin , Andreas Schumacher , Bradley Barnett , C. Eary , Robert Kaus , Timothy Kercher , Weidong Liu , Michael Lyon , Paul Nichols , Bin Wang , Tarek Sammakia , April Kennedy , Yutong Jiang
发明人： Lawrence Blatt , Scott Seiwert , Steven Andrews , Pierre Martin , Andreas Schumacher , Bradley Barnett , C. Eary , Robert Kaus , Timothy Kercher , Weidong Liu , Michael Lyon , Paul Nichols , Bin Wang , Tarek Sammakia , April Kennedy , Yutong Jiang
IPC分类号： A61K38/12
CPC分类号： C07K5/0806 , A61K38/00 , A61K38/1793 , A61K38/212 , A61K38/217 , A61K38/2292 , A61K38/55 , C07D471/04 , C07D487/04 , C07K5/0804 , A61K2300/00
摘要： The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
摘要翻译： 实施方案提供通式I至通式VIII的化合物，以及包含主题化合物的组合物，包括药物组合物。 实施方案还提供治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，所述方法通常涉及向有需要的个体施用有效量的主题化合物或组合物。
-
公开(公告)号：US10153273B1
公开(公告)日：2018-12-11
申请号：US15832377
申请日：2017-12-05
申请人： Roger S. Tsai , Weidong Liu , Yeong-Chang Chou
发明人： Roger S. Tsai , Weidong Liu , Yeong-Chang Chou
IPC分类号： H01L27/06 , H01L29/207 , H01L29/423 , H01L29/778 , H01L29/80 , H01L49/02 , H01L21/8252 , H01L29/66 , H01L21/764 , H01L21/74 , H01L21/285 , H01L21/3213 , H01L23/528 , H01L23/482 , H01L23/66 , H01L29/205
摘要： A semiconductor device is provided that comprises a base structure, a first channel layer overlying the base structure, a second channel layer overlying the first channel layer, and first, second, and third ohmic contacts overlying the second channel layer. The semiconductor device further comprises a metal-semiconductor heterodimension field effect transistor that is formed between the first and second ohmic contacts, the metal-semiconductor heterodimension field effect transistor including a first gate formed through the first and second channel layers. The semiconductor device yet further comprises a high electron mobility transistor formed between the second and third ohmic contacts, the high electron mobility transistor including a second gate formed through the second channel layer without extending through the first channel layer.
-
8.发明授权N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases 有权N4-苯基 - 喹唑啉-4-胺衍生物和相关化合物作为用于治疗过度增殖性疾病的ErbB I型受体酪氨酸激酶抑制剂公开(公告)号：US08648087B2
公开(公告)日：2014-02-11
申请号：US12085048
申请日：2006-11-15
申请人： Joseph P. Lyssikatos , Julie Marie Greschuk , Fredrik P. Marmsäter , Qian Zhao , D. David Hennings , Weidong Liu
发明人： Joseph P. Lyssikatos , Julie Marie Greschuk , Fredrik P. Marmsäter , Qian Zhao , D. David Hennings , Weidong Liu
IPC分类号： A01N43/54 , A61K31/517 , C07D239/72 , C07D401/00
CPC分类号： A61K31/337 , A61K31/513 , A61K31/517 , A61K39/3955 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D495/04 , C07D519/00
摘要： This invention provides compounds of Formula I wherein B, G, A, E, R1, R2, R3, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.
摘要翻译： 本发明提供式I化合物，其中B，G，A，E，R 1，R 2，R 3，m和n如本文所定义，其可用作I型受体酪氨酸激酶抑制剂，及其用于治疗 哺乳动物过度增生性疾病。
-
9.发明申请A METHOD OF ENHANCING MIR-185 EXPRESSION TO REDUCE LOW DENSITY LIPOPROTEIN/CHOLESTEROL ACCUMULATION IN A CELL 有权一种增强MIR-185表达以减少细胞中低密度脂蛋白/胆固醇积累的方法公开(公告)号：US20130337459A1
公开(公告)日：2013-12-19
申请号：US13919141
申请日：2013-06-17
IPC分类号： C12N15/113 , C12Q1/68
CPC分类号： C12N15/113 , C12N15/1137 , C12N15/1138 , C12N2310/141 , C12Q1/6883 , C12Q2600/158 , C12Q2600/178 , C12Y101/01034 , C12Y205/01021
摘要： The present invention provides a method of quantifying miR-185 as a potential biomarker in lipid disorder or cardiovascular diseases in human. The present invention also provides a method of modulating miR-185 in regulating LDL and cholesterol metabolism in cells. The present invention has therapeutic potential in the treatment of cholesterol/LDL related cardiovascular diseases in humans.
摘要翻译： 本发明提供了定量miR-185作为人类脂质障碍或心血管疾病的潜在生物标志物的方法。 本发明还提供调节miR-185调节细胞中LDL和胆固醇代谢的方法。 本发明在治疗人类胆固醇/低密度脂蛋白相关心血管疾病方面具有治疗潜力。
-
公开(公告)号：USD671866S1
公开(公告)日：2012-12-04
申请号：US29371635
申请日：2011-06-15
申请人： Weidong Liu , Er-xue Wang
设计人： Weidong Liu , Er-xue Wang
-
-
-
-
-
-
-
-
-
搜索结果
50 条记录 (耗时 0.082 秒)
